A Petach Tikvah company has developed a first of its kind wireless medical monitoring system that enables monitoring of coronavirus patients without hospitalization, reducing contact between them and medical teams, and preventing the risk of doctors and nurses being infected.
The BioBeat system, using a sticker affixed to the patient’s chest, continuously monitors 16 advanced physiologic metrics such as respiratory rate, blood oxygen percentage, pulse, continuous blood pressure, HRV, heart rate, heart output, body temperature, SVR and patient movement. The data is transmitted via BT to a cloud that complies with the medical information security standard and is transmitted to all communication media including cellphones, tablets, computers and television screens.
“Currently, the company has deployed advanced monitoring systems in all coronavirus isolation units at 15 medical centers in Israel, including: Ichilov Hospital, Tel Hashomer, Rambam, Shaare Zedek and more,” said CEO Arik Ben Ishai.
The company is the only company in the world to hold FDA approval, which was issued in August 2019, for continuous blood pressure measurement without the need for a pressure cuff.
Completion of deployment in all hospitals has already enabled support for most of the coronavirus medical staff in the isolation units. The information is passed directly to the staff and without direct contact.
In addition, BioBeat is preparing to provide an advanced solution for home hospitalization, and its employees are working to adjust the system as needed. In addition to monitoring itself, the system enables advanced analysis of the physiological effect of the virus on humans, as well as assessing the effectiveness of medical care provided to patients.
BioBeat stands at the forefront of the response and supports the medical teams.
To date, the company has raised $2.5 million with revenues of more than $10 million.
BioBeat is owned by three founders: Ishay, Johanan May, VP of technology, and Israel Sarussi VP of research and development.